Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27509383 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1PKMADORA2B | |
| SCHEMBL7466936 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1PKMADORA2B | |
| SCHEMBL3088031 | 0.77 | MEN1 (0.41) | ALDH1A1KMT2AMEN1GAAADORA3 | |
| SCHEMBL3088041 | 0.77 | MEN1 (0.41) | ALDH1A1KMT2AMEN1GAAADORA3 | |
| SCHEMBL6332675 | 0.77 | MEN1 (0.41) | ALDH1A1KMT2AMEN1GAAADORA3 | |
| SCHEMBL3088036 | 0.77 | MEN1 (0.41) | ALDH1A1KMT2AMEN1GAAADORA3 | |
| SCHEMBL7458765 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1PKMADORA2B | |
| SCHEMBL8314886 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1PKMADORA2B | |
| SCHEMBL7458769 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1PKMADORA2B | |
| SCHEMBL7457049 | 0.72 | ALDH1A1 (0.42) | ALDH1A1KMT2AADORA2BL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455575-B2 | ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| EP-0639577-B1 | Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents | BRISTOL MYERS SQUIBB CO (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0590267-B1 | Deoxy taxols | BRISTOL MYERS SQUIBB CO (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-0694539-B1 | 7-O-Ethers of taxane derivatives | BRISTOL MYERS SQUIBB CO (US) | 2001-11-28 | — | — | EP | disclosed |
| US-20010023255-A1 | PHOSPHONOOXYMETHYL ETHERS OF TAXANE DERIVATIVES | GOLIK JERZY (US) | 2001-09-20 | — | — | US | disclosed |
| US-6201140-B1 | ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-03-13 | — | — | US | disclosed |
| EP-0600517-B1 | 6,7-Modified paclitaxels | BRISTOL MYERS SQUIBB CO (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0604910-B1 | Phosphonooxymethyl ethers of taxane derivatives | BRISTOL MYERS SQUIBB CO (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0671399-B1 | 6,7-Epoxy paclitaxels | BRISTOL MYERS SQUIBB CO (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5693666-A | USED IN TREATING MAMMALIAN TUMORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5478854-A | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| EP-0671399-A1 | 6,7-Epoxy paclitaxels | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5395850-A | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| EP-0639577-A1 | Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5380751-A | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0604910-A1 | Phosphonooxymethyl ethers of taxane derivatives | Bristol-Myers Squibb Company (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0600517-A1 | 6,7-Modified paclitaxels | Bristol-Myers Squibb Company (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0590267-A2 | Deoxy taxols | Bristol-Myers Squibb Company (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5294637-A | Fluoro taxols | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0577082-A1 | Fluoro taxols with antitumor activity | Bristol-Myers Squibb Company (US) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023255-A1 | PHOSPHONOOXYMETHYL ETHERS OF TAXANE DERIVATIVES | PHOSPHO1, MTMR1, PIK3CA | ALDH1A1 2892/4885KMT2A 2027/4885MEN1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.